During the past decade, Lux Med conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Lux Med" are "Melanoma" (1 trials) and "Metastatic or Unresectable Cutaneous Melanoma" (1 trials). Many other conditions were trialed in "Lux Med" in a lesser frequency.

Most popular intervention types in "Lux Med" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "MEK162" (2 trials), "Dacarbazine" (1 trials), "LGX818" (1 trials) and "vemurafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lux Med" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Lux Med". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Lux Med, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Lux Med, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Lux Med has several departments that took part in Clinical trials: "LUX MED Onkologia Sp. z o.o." - 4 trials, "MAGODENT Sp. z o.o. Szpital Elblaska" - 2 trials